Press "Enter" to skip to content

White House Drops Heidi Overton’s FDA Nomination

Key takeaways:

  • The White House confirmed Tuesday that it is dropping Overton’s nomination a day before a scheduled Senate committee vote.
  • Several Republican senators had not committed to supporting Overton, while CBS News reported that no committee Democrats were expected to back her.
  • The FDA has been led by acting Commissioner Kyle Diamantas since Marty Makary’s departure in May.

The White House is dropping Dr. Heidi Overton’s nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday, one day before a Senate committee was scheduled to vote on whether to advance her to the full Senate.

The decision follows weeks of uncertainty about whether Overton, a White House domestic policy official and preventive medicine doctor, could win enough Republican support on the Senate Health, Education, Labor and Pensions Committee. CBS News reported that no Democrats on the panel were expected to back her and that the White House had begun speaking with other potential candidates, including people who could serve as acting commissioner without Senate confirmation.

Committee Chairman Sen. Bill Cassidy, a Louisiana Republican, had questioned whether Overton had enough experience to run the FDA. He also described her association with President Donald Trump’s efforts concerning childhood vaccination as “almost disqualifying,” CBS News reported. Cassidy said Sunday that he remained uncertain whether the committee would advance her nomination and did not say how he would vote.

Cassidy said the committee also had to weigh the prospect of leaving the agency in the hands of successive temporary leaders. “Do we want a series of short-term administrators who probably will have more influence from the secretary,” he asked, rather than a permanent commissioner able to establish some independence.

Sen. Susan Collins, a Maine Republican, told NBC News last week that she had “not taken a position” and needed “to get some answers on various things.” CBS News reported that Sen. Lisa Murkowski, an Alaska Republican, had also not said how she would vote. During Overton’s confirmation hearing, Murkowski asked whether she would restrict mifepristone, a medication used in more than half of U.S. abortions, according to CBS News.

Questions about mifepristone were central to the opposition Overton faced. She has praised the Supreme Court’s decision overturning Roe v. Wade and called for strict restrictions on medication abortion. CBS News reported that Sen. Josh Hawley, a Missouri Republican, was among those dissatisfied with her answers about an FDA safety study of mifepristone. The anti-abortion group Susan B. Anthony urged the Senate to delay her confirmation and sought an FDA commitment to ban mail orders of the drug. The FDA is set to finish its safety review in March, according to NBC News.

Overton’s work on Trump’s vaping policies while serving on the White House Domestic Policy Council also drew scrutiny, CBS News reported. Before joining the White House, she was chief policy officer at the conservative America First Policy Institute. Supporters pointed to her medical background and endorsements from two former FDA commissioners, according to CBS News.

The FDA has lacked a permanent commissioner since Dr. Marty Makary left in May. NBC News reported that he resigned in part over the administration’s decision to authorize several fruit-flavored vaping products; CBS News described his departure as a White House ouster amid pressure over flavored vapes. Makary told CBS News this month that he refused pressure to approve fruit-flavored products that “appeal to children.” Acting Commissioner Kyle Diamantas has led the agency since his departure, CBS News reported.

Overton faced a narrow confirmation window: Democrats take control of the Senate in January, when her nomination would have required resubmission, according to NBC News.

Sources

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Share via
Copy link
Powered by Social Snap